Free Trial

Inhibikase Therapeutics (IKT) News Today

Inhibikase Therapeutics logo
$1.84 +0.05 (+2.79%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$1.82 -0.02 (-1.03%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IKT Latest News

IKT Inhibikase Therapeutics, Inc. - Seeking Alpha
Inhibikase Therapeutics announces appointment of McIntyre as CFO
Inhibikase Therapeutics (IKT) Receives a Hold from H.C. Wainwright
Inhibikase Announces Expansion of Senior Leadership Team
Inhibikase Therapeutics appoints Mark Iwicki as CEO
What is HC Wainwright's Estimate for IKT Q1 Earnings?
Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Get Inhibikase Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IKT Media Mentions By Week

IKT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IKT
News Sentiment

1.67

1.03

Average
Medical
News Sentiment

IKT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IKT Articles
This Week

1

1

IKT Articles
Average Week

Get the Latest News and Ratings for IKT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NYSE:IKT) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners